Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - FactSet shares fall as weak full-year guidance overshadows positive Q4 revenue surprise

BUZZ - FactSet shares fall as weak full-year guidance overshadows positive Q4 revenue surprise

路透社路透社2026/09/30 12:02
Show original

- ** After FactSet Research Systems (FDS.N) released its fourth-quarter earnings report, the share price fell about 4%, closing at $255.

** According to data compiled by London Stock Exchange Group (LSEG), the financial data provider expects earnings per share (EPS) for fiscal year 2027 to be between $17 and $17.50, lower than the analyst average estimate of $17.85.

** Net profit for the quarter dropped to $121.1 million from $153.6 million in the same period last year.

** Fourth-quarter revenue was $634.7 million, higher than the expected $629.8 million.

** Of 20 brokerages, 4 gave a "buy" or higher rating, 10 rated it as "hold," 5 as "sell," and 1 as "strong sell"; the median target price is $281.77.

** As of the close of the previous trading day, the stock had declined by 10.41% for the year to date.


(To facilitate non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the translated text and provides it for readers’ convenience only. Reuters assumes no responsibility for any damage or loss arising from use of the automated translation function.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Roche (RHHBY.US) BTK inhibitor submitted for listing

On September 30, Roche (RHHBY.US) announced that the U.S. FDA has accepted the New Drug Application (NDA) for its non-covalent BTK inhibitor, fenebrutinib.

智通财经•2026/09/30 15:26